摘要
骨髓间充质干细胞具有自我更新、自我复制的多向分化潜能,使其成为治疗缺血性心脏病的研究热点,可通过促进心肌细胞、血管生成,减少心律失常的发生,抑制缺血/再灌注对心肌的损伤而减轻心肌重构,改善心功能。而自体干细胞移植不涉及伦理学问题,不存在免疫排斥反应,细胞易获得,已在临床应用并获得了一定的疗效。骨髓间充质干细胞以其独特的优势必将为缺血性心脏病的治疗带来希望。
Bone marrow mesenchymal stem cells（BMSCs）have multiplex differentiation potential of self-renewal and self-replicating,making it a research hotspot of ischemic heart disease treatment,which can reduce arrhythmia by promoting myocardial cell,angiogenesis,,inhibit myocardial ischemia and reperfusion injury and reduce cardiac remodeling,thus improve cardiac function.And self-stem cell transplantation does not involve ethical problem,does not have immune rejection,and the cells are easy to obtain,which has already achieved a certain curative effect in the clinical application.BMSCs will surely bring hopes for the treatment of ischemic heart disease with its unique advantages.
出处
《医学综述》
2012年第16期2557-2559,共3页
Medical Recapitulate
关键词
骨髓间充质干细胞
缺血性心脏病
研究进展
Bone marrow mesenchymal stem cells
Ischemic heart disease
Research progress
